?$defaultResponsive$)
*Today, we are CarelonRx, but when we created some of these documents, we were IngenioRx. This name change doesn’t impact our dedication to driving cost savings, personalizing customer experiences, and improving whole-person health.
Clinical reports
Drug Insights Q4-2022
IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...
Drug + Biologic Pipeline Q4 2022
We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.
IngenioRx Drug Insights Q3 2022
IngenioRx’s Q3 2022 DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new...
Drug + Biologic Pipeline Q3 2022
IngenioRx closely monitors drugs, biologics, and gene therapies in development. Our Q3 2022 IngenioRx Drug and Biologic Pipeline...
2021 IngenioRx Drug Trend Report*
How did we keep trend and spend down despite the effects of utilization, inflation, and new drugs introduced to the market?
Drug Insights Q2 2022
IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...
Drug + Biologic Pipeline Q2 2022
We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food...
Drug Insights Q1-2022
IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular...
Drug + Biologic Pipeline Q1-2022
IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food and Drug...
Drug Insights Q4-2021*
IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities,...
Drug + Biologic Pipeline Q4-2021
We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.
Drug + Biologic Pipeline Q3-2021
We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming FDA...
...